Prescription digital therapeutics, evidence-based software treatments, and the fight for a working business model.
The FDA-CMS pilot lets prescribers administer DTx products before clearance, with real-world data feeding both the clearance decision and Medicare coverage. Early DMHT billing shows demand — 446 patients in Q3 2025, up from 99 in Q1.
With payers scrutinizing what happens after patients stop GLP-1s, Noom is giving away structured behavioral support — claiming members regain less than 2% of body weight in the year after stopping medication.
Most digital sleep therapeutics were validated on younger adults. A Montreal-led RCT of the eCBT+ program shows the guideline-recommended therapy works in the population that needs it most — with accessibility designed in.
The Series D hands Click full commercial rights to CT-155, which met its primary endpoint in the CONVOKE pivotal study. The simultaneous layoffs show how surviving DTx firms are restructuring around pharma-funded commercialization.